ADI PEG20

DRUG5 trials

Sponsors

Polaris Group, Queen Mary University of London, Memorial Sloan Kettering Cancer Center, Washington University School of Medicine

Conditions

Advanced Solid CancersCarcinoma, Non-Small-Cell LungSarcoma,Soft TissueSoft Tissue SarcomaStsUveal Melanoma

Phase 1

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

TerminatedNCT03254732

Polaris GroupAdvanced Solid Cancers

Start: 2017-07-14End: 2020-02-25Updated: 2022-04-27

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

WithdrawnNCT03498222

Queen Mary University of LondonCarcinoma, Non-Small-Cell Lung

Start: 2018-06-01End: 2021-12-31Updated: 2020-02-25

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

CompletedNCT03922880

Memorial Sloan Kettering Cancer CenterUveal Melanoma

Start: 2019-04-16End: 2023-01-20Updated: 2025-05-15

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

TerminatedNCT05813327

Washington University School of MedicineSarcoma,Soft Tissue, Soft Tissue Sarcoma, Sts

Start: 2024-03-14End: 2026-07-22Updated: 2026-09-03

Phase 3

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

TerminatedNCT05712694

Polaris GroupSoft Tissue Sarcoma

Start: 2023-11-29End: 2026-05-25Updated: 2026-06-25

Related Papers

A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.

Journal of Clinical Oncology2024-06-01

A Phase 1 study of <scp>ADI‐PEG20</scp> (pegargiminase) combined with cisplatin and pemetrexed in <scp>ASS1‐negative</scp> metastatic uveal melanoma

Pigment Cell & Melanoma Research2022-04-2525 citations

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.

2020-09-0322 citations

Abstract 2217: Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapy

Cancer Research2020-08-153 citations

A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.

Journal of Clinical Oncology2018-05-208 citations